{"body": "Is autosomal dominant inheritanced form of Osteogenesis imperfecta caused by mutations in the genes associated with collagen production?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27312322", "http://www.ncbi.nlm.nih.gov/pubmed/2992938", "http://www.ncbi.nlm.nih.gov/pubmed/27677223", "http://www.ncbi.nlm.nih.gov/pubmed/21567925", "http://www.ncbi.nlm.nih.gov/pubmed/22863195", "http://www.ncbi.nlm.nih.gov/pubmed/28116328", "http://www.ncbi.nlm.nih.gov/pubmed/18566967", "http://www.ncbi.nlm.nih.gov/pubmed/27510842", "http://www.ncbi.nlm.nih.gov/pubmed/21341209", "http://www.ncbi.nlm.nih.gov/pubmed/28820180", "http://www.ncbi.nlm.nih.gov/pubmed/2886666", "http://www.ncbi.nlm.nih.gov/pubmed/24928016", "http://www.ncbi.nlm.nih.gov/pubmed/29150909", "http://www.ncbi.nlm.nih.gov/pubmed/2037280", "http://www.ncbi.nlm.nih.gov/pubmed/8456806", "http://www.ncbi.nlm.nih.gov/pubmed/27762305", "http://www.ncbi.nlm.nih.gov/pubmed/21667357", "http://www.ncbi.nlm.nih.gov/pubmed/19533842", "http://www.ncbi.nlm.nih.gov/pubmed/25402547", "http://www.ncbi.nlm.nih.gov/pubmed/20839288", "http://www.ncbi.nlm.nih.gov/pubmed/12362985"], "ideal_answer": ["Osteogenesis imperfecta (OI), also known as brittle bone disease, is a group of genetic disorders that mainly affect the bones. The autosomal dominant form of the disease is cause by a mutation in the COL1A1 or COL1A2 genes which produce type I collagen.", "steogenesis imperfecta (OI) is a heterogeneous bone disorder characterized by recurrent fractures. Although most cases of OI have heterozygous mutations inCOL1A1orCOL1A2and show autosomal dominant inheritance,"], "exact_answer": "yes", "concepts": ["http://www.biosemantics.org/jochem#4249099", "http://www.disease-ontology.org/api/metadata/DOID:0110341", "http://www.disease-ontology.org/api/metadata/DOID:0110340", "http://www.disease-ontology.org/api/metadata/DOID:0110343", "http://www.disease-ontology.org/api/metadata/DOID:0110337", "http://www.disease-ontology.org/api/metadata/DOID:0110338", "http://www.disease-ontology.org/api/metadata/DOID:0110342", "http://www.disease-ontology.org/api/metadata/DOID:0110336", "http://www.disease-ontology.org/api/metadata/DOID:0110335", "https://meshb.nlm.nih.gov/record/ui?ui=D010013", "http://www.disease-ontology.org/api/metadata/DOID:0110334", "http://www.disease-ontology.org/api/metadata/DOID:12347", "https://meshb.nlm.nih.gov/record/ui?ui=D005799"], "type": "yesno", "id": "5a6f77d7b750ff4455000051", "snippets": [{"offsetInBeginSection": 13, "offsetInEndSection": 222, "text": "steogenesis imperfecta (OI) is a heterogeneous bone disorder characterized by recurrent fractures. Although most cases of OI have heterozygous mutations inCOL1A1orCOL1A2and show autosomal dominant inheritance,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28116328", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 274, "text": "Osteogenesis imperfecta (OI) is a group of hereditary disorders characterized by decreased bone mass and increased fracture risk. The majority of OI cases have an autosomal dominant pattern of inheritance and are usually caused by mutations in genes encoding type I collagen", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27762305", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 281, "text": " Osteogenesis imperfecta (OI) is a group of hereditary disorders characterized by low bone mass and recurrent fractures. Most OI cases follow an autosomal dominant pattern of inheritance and are attributed to mutations in genes encoding type I collagen (COL1A1/COL1A2). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27312322", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 268, "text": "Osteogenesis imperfecta (OI) is a genetic disorder characterised by low bone mineral density resulting in fractures. 85-90% of patients with OI carry a variant in the type 1 collagen genes, COL1A1 and COL1A2, which follows an autosomal dominant pattern of inheritance.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27677223", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 385, "text": "Osteogenesis imperfecta (OI) comprises a heterogeneous group of disorders that are characterized by susceptibility to bone fractures, and range in severity from a subtle increase in fracture frequency to death in the perinatal period. Most patients have defects in type I collagen biosynthesis with autosomal-dominant inheritance, but many autosomal-recessive genes have been reported.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25402547", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 159, "text": "To investigate mutation of COL1A1 gene and analyze the relationship between genotype and clinical phenotype in a family with osteogenesis imperfecta", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24928016", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 135, "text": "Dominant inheritance of osteogenesis imperfecta (OI) is caused by mutations in COL1A1 or COL1A2, the genes that encode type I collagen,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21667357", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 805, "text": "Osteogenesis imperfecta (OI) is a heterogeneous group of inherited disorders of bone formation, resulting in low bone mass and an increased propensity to fracture. It exhibits a broad spectrum of clinical severity, ranging from multiple fractures in utero and perinatal death, to normal adult stature and low fracture incidence. Extra-skeletal features of OI include blue sclera, hearing loss, skin hyperlaxity, joint hyperextensibility, and dentinogenesis imperfecta. The proα1(I) and proα2(I) chains of collagen 1 are encoded by the COL1A1 and COL1A2 genes, respectively; quantitative or qualitative defects in type I collagen synthesis usually manifest as types of OI or some sub-types of EDS. The majority of patients (about 90%) with a clinical diagnosis of OI have a mutation in the COL1A1 or COL1A2", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21567925", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 478, "text": "Osteogenesis imperfecta (OI) type I is characterized by bone fragility without significant deformity, osteopenia, normal stature, blue sclerae, and autosomal dominant inheritance. Dermal fibroblasts from most affected individuals produce about half the expected amount of type I collagen, suggesting that the OI type I phenotype results from a variety of mutations which alter the apparent expression of either COL1A1 or COL1A2, the genes encoding the chains of type I collagen.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8456806", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "Autosomal dominant osteogenesis imperfecta is caused by mutations in the COL1A2 and COL1A1 genes of type I collagen. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2886666", "endSection": "abstract"}, {"offsetInBeginSection": 352, "offsetInEndSection": 544, "text": "Osteogenesis imperfecta is caused by dominant autosomal mutations in the type I collagen coding genes (COL1A1 and COL1A2) in about 85% of individuals, affecting collagen quantity or structure.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28820180", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 165, "text": "Osteogenesis imperfecta (OI) is a heterogeneous group of disorders of connective tissue, mainly caused by mutations in the collagen type I genes (COL1A1 and COL1A2).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27510842", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "Autosomal dominant osteogenesis imperfecta (OI) is caused by mutations in the genes (COL1A1 or COL1A2) encoding the chains of type I collagen.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18566967", "endSection": "abstract"}, {"offsetInBeginSection": 126, "offsetInEndSection": 326, "text": "In approximately 90% of individuals with osteogenesis imperfecta, mutations in either of the genes encoding the pro-alpha1 or pro-alpha2 chains of type I collagen (COL1A1 or COL1A2) can be identified.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19533842", "endSection": "abstract"}, {"offsetInBeginSection": 187, "offsetInEndSection": 303, "text": "Autosomal dominant OI is caused by mutations in the genes (COL1A1 or COL1A2) encoding the chains of type I collagen.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20839288", "endSection": "abstract"}, {"offsetInBeginSection": 265, "offsetInEndSection": 659, "text": "ext-generation sequencing technology was used to screen a panel of known OI genes.RESULTS: In 41 probands, we identified 28 different disease-causing variants of 9 different known OI genes. Eleven of the variants are novel. Ten of the 28 variants are located in COL1A1, five in COL1A2, three in BMP1, three in FKBP10, two in TMEM38B, two in P3H1, and one each in CRTAP, SERPINF1, and SERPINH1. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29150909", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 307, "text": "Osteogenesis imperfecta (OI) is a clinically and genetically heterogeneous disorder associated with bone fragility and susceptibility to fractures after minimal trauma. OI type V has an autosomal-dominant pattern of inheritance and is not caused by mutations in the type I collagen genes COL1A1 and COL1A2. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22863195", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 163, "text": "Detection of a high frequency RsaI polymorphism in the human pro alpha 2(I) collagen gene which is linked to an autosomal dominant form of osteogenesis imperfecta.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2992938", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Osteogenesis imperfecta due to recurrent point mutations at CpG dinucleotides in the COL1A1 gene of type I collagen.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2037280", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 375, "text": "Osteogenesis imperfecta (OI), commonly known as \"brittle bone disease\", is a dominant autosomal disorder characterized by bone fragility and abnormalities of connective tissue. Biochemical and molecular genetic studies have shown that the vast majority of affected individuals have mutations in either the COL1A1 or COL1A2 genes that encode the chains of type I procollagen. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12362985", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Osteogenesis imperfecta is normally caused by an autosomal dominant mutation in the type I collagen genes COL1A1 and COL1A2.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21341209", "endSection": "abstract"}]}
{"body": "Mutations in which gene determine response to both erlotinib and gefitinib?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21430269", "http://www.ncbi.nlm.nih.gov/pubmed/22263058", "http://www.ncbi.nlm.nih.gov/pubmed/22738915", "http://www.ncbi.nlm.nih.gov/pubmed/23332287", "http://www.ncbi.nlm.nih.gov/pubmed/18799900", "http://www.ncbi.nlm.nih.gov/pubmed/19063875", "http://www.ncbi.nlm.nih.gov/pubmed/21777765", "http://www.ncbi.nlm.nih.gov/pubmed/19808904", "http://www.ncbi.nlm.nih.gov/pubmed/17575237", "http://www.ncbi.nlm.nih.gov/pubmed/17145836", "http://www.ncbi.nlm.nih.gov/pubmed/18997733", "http://www.ncbi.nlm.nih.gov/pubmed/20647703", "http://www.ncbi.nlm.nih.gov/pubmed/20705455", "http://www.ncbi.nlm.nih.gov/pubmed/15737014", "http://www.ncbi.nlm.nih.gov/pubmed/16199108", "http://www.ncbi.nlm.nih.gov/pubmed/16730855", "http://www.ncbi.nlm.nih.gov/pubmed/16009451", "http://www.ncbi.nlm.nih.gov/pubmed/22806307", "http://www.ncbi.nlm.nih.gov/pubmed/23507588", "http://www.ncbi.nlm.nih.gov/pubmed/16049312", "http://www.ncbi.nlm.nih.gov/pubmed/22920167", "http://www.ncbi.nlm.nih.gov/pubmed/20948254", "http://www.ncbi.nlm.nih.gov/pubmed/20512075", "http://www.ncbi.nlm.nih.gov/pubmed/18726117", "http://www.ncbi.nlm.nih.gov/pubmed/20007486", "http://www.ncbi.nlm.nih.gov/pubmed/21904575", "http://www.ncbi.nlm.nih.gov/pubmed/16705038", "http://www.ncbi.nlm.nih.gov/pubmed/15329413"], "triples": [{"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A7647895", "o": "Gene Mutation"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0596611", "o": "http://linkedlifedata.com/resource/umls/label/A7850263"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A7850263", "o": "Gene Mutation"}], "ideal_answer": ["Patients who carry somatic activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene, respond well to erlotinib and gefitinib."], "exact_answer": ["epidermal growth factor receptor (EGFR) gene"], "concepts": ["http://www.biosemantics.org/jochem#4274201", "http://www.biosemantics.org/jochem#4241662", "http://www.biosemantics.org/jochem#4241661"], "type": "factoid", "id": "51542e44d24251bc05000081", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Mutations in the epidermal growth factor receptor gene (EGFR) are frequently observed in non-small-cell lung cancer (NSCLC),", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23332287", "endSection": "sections.0"}, {"offsetInBeginSection": 223, "offsetInEndSection": 445, "text": "EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, have transformed therapy for patients with EGFR-mutant NSCLC and have proved superior to chemotherapy as first-line treatment for this patient group.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23332287", "endSection": "sections.0"}, {"offsetInBeginSection": 53, "offsetInEndSection": 361, "text": "Adenocarcinomas, the most common histologic subtype of non-small cell lung cancer (NSCLC), are frequently associated with activating mutations in the epidermal growth factor receptor (EGFR) gene. Although these patients often respond clinically to the EGFR tyrosine kinase inhibitors erlotinib and gefitinib,", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22738915", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 341, "text": "Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib are promising therapies for patients with advanced non-small-cell lung cancer (NSCLC). Patients with somatic activating mutations in the EGFR gene have dramatic response initially, but would eventually develop resistance to these TKIs.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22263058", "endSection": "sections.0"}, {"offsetInBeginSection": 242, "offsetInEndSection": 546, "text": "NSCLCs with EGFR mutations (exon 19 deletions or the exon 21 L858R) attain responses to EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, with improved response rate (RR), progression-free survival (PFS) and in some reports overall survival (OS) when compared with EGFR wildtype (WT) cases.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21904575", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 216, "text": "Patients presenting with non-small cell lung cancer (NSCLC) and active EGFR mutation have a high response rate (60-70%) to EGFR tyrosine kinase inhibitors (TKI) with little immediate progression (primary resistance).", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21777765", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 163, "text": "Lung cancers harboring mutations in the epidermal growth factor receptor (EGFR) respond to EGFR tyrosine kinase inhibitors, but drug resistance invariably emerges.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21430269", "endSection": "sections.0"}, {"offsetInBeginSection": 12, "offsetInEndSection": 141, "text": "EGFR-TKI yields a long survival period in cases of non-small cell lung cancer (NSCLC), especially those with EGFR gene mutations,", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20948254", "endSection": "sections.0"}, {"offsetInBeginSection": 582, "offsetInEndSection": 706, "text": "Efficacy of erlotinib was recognized in the cases in which disease control was obtained by initial treatment with gefitinib.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20948254", "endSection": "sections.0"}, {"offsetInBeginSection": 12, "offsetInEndSection": 205, "text": "Patients with lung adenocarcinoma who carry epidermal growth factor receptor (EGFR) gene mutations respond remarkably well to EGFR tyrosine kinase inhibitor (EGFR-TKI), gefitinib, or erlotinib.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20705455", "endSection": "sections.0"}, {"offsetInBeginSection": 24, "offsetInEndSection": 188, "text": "lung adenocarcinomas with epidermal growth factor receptor (EGFR) mutations respond to treatment with the tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib;", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20007486", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 204, "text": "The development of resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) seems almost inevitable, even in patients with lung cancer that initially respond well to EGFR-TKIs.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19808904", "endSection": "sections.0"}, {"offsetInBeginSection": 425, "offsetInEndSection": 823, "text": "Gefitinib- or erlotinib-resistant sublines were established by exposing the parental PC-9 cell line to chronic, repeated treatments with these drugs. These resistant sublines showed more than 100-fold more resistance to gefitinib and erlotinib and acquired cross-resistance to other EGFR-TKIs. The T790M EGFR mutation was found by pyrosequencing, and this seemed to be the cause of drug resistance.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19808904", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 229, "text": "Patients with advanced pulmonary adenocarcinoma exhibiting overexpression or mutation of epidermal growth factor receptor tend to respond better to targeted therapy with tyrosine kinase inhibitors such as gefitinib and erlotinib.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18997733", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 496, "text": "Mutations of the epidermal growth factor receptor (EGFR) gene have been reported in non-small-cell lung cancer (NSCLC), especially in patients with adenocarcinoma and never smokers. Some common somatic mutations in EGFR, including deletion mutations in exon 19 and leucine-to-arginine substitution at amino acid position 858 (L858R) in exon 21, have been examined for their ability to predict sensitivity to gefitinib or erlotinib, which are selective EGFR tyrosine kinase inhibitors (EGFR-TKIs).", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16730855", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 249, "text": "Somatic mutations in exons encoding the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene are found in human lung adenocarcinomas and are associated with sensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16705038", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 196, "text": "Somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene are present in lung adenocarcinomas that respond to the EGFR inhibitors gefitinib and erlotinib.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16049312", "endSection": "sections.0"}, {"offsetInBeginSection": 325, "offsetInEndSection": 523, "text": "Epidermal growth factor receptor(EGFR)-tyrosine kinase inhibitor(TKI)(such as gefitinib or erlotinib)treatment of lung cancer harboring EGFR gene mutation is one of the prototypes of such therapies.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23507588", "endSection": "sections.0"}, {"offsetInBeginSection": 380, "offsetInEndSection": 630, "text": "patients with NSCLC and CNS metastases with epidermal growth factor receptor gene mutations who received CSF examinations during epidermal growth factor receptor-tyrosine kinase inhibitors treatment (250 mg daily gefitinib or 150 mg daily erlotinib).", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22806307", "endSection": "sections.0"}, {"offsetInBeginSection": 491, "offsetInEndSection": 707, "text": "The evidence of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) such as gefitinib and erlotinib was first confirmed as the second-line treatment for non-selective patients with advanced NSCLC.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20647703", "endSection": "sections.0"}, {"offsetInBeginSection": 927, "offsetInEndSection": 1402, "text": "patients with EGFR-mutated advanced NSCLC, the first-line treatment with gefitinib had achieved a significant prolongation of progression-free survival compared with standard platinum doublet chemotherapy in a few phase III trials, and became a new standard of care. Gefitinib is highly effective for patients with advanced NSCLC with EGFR mutation even if their performance status is poor, although one should always pay careful attention to fatal interstitial lung disease.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20647703", "endSection": "sections.0"}, {"offsetInBeginSection": 11, "offsetInEndSection": 187, "text": "The tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are effective in non-small cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene mutations.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20512075", "endSection": "sections.0"}, {"offsetInBeginSection": 12, "offsetInEndSection": 226, "text": "Somatic mutations in the epidermal growth factor receptor (EGFR) gene are associated with the responses to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with non-small-cell lung cancer (NSCLC).", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19063875", "endSection": "sections.0"}, {"offsetInBeginSection": 1051, "offsetInEndSection": 1393, "text": "EGFR tyrosine kinase inhibitors (gefitinib, erlotinib), which are molecularly targeted drugs, and it has now become possible to select treatment methods by choosing from a number of anticancer drugs. EGFR tyrosine kinase inhibitors have been demonstrated to have a very high cytoreductive effect on lung cancers that have EGFR gene mutations.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18799900", "endSection": "sections.0"}, {"offsetInBeginSection": 224, "offsetInEndSection": 385, "text": "EGFR gene mutations at kinase domain in non-small cell lung cancer (NSCLC) have been examined for their ability to predict sensitivity to gefitinib or erlotinib.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18726117", "endSection": "sections.0"}, {"offsetInBeginSection": 214, "offsetInEndSection": 386, "text": "responsive patients can relapse as a result of selection for EGFR gene mutations that confer resistance to ATP competitive EGFR inhibitors, such as erlotinib and gefitinib.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17575237", "endSection": "sections.0"}, {"offsetInBeginSection": 28, "offsetInEndSection": 254, "text": "the epidermal growth factor receptor (EGFR) was a therapeutic target in non-small cell lung cancer (NSCLC) and other cancers led to development of the small-molecule receptor tyrosine kinase inhibitors gefitinib and erlotinib.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17145836", "endSection": "sections.0"}, {"offsetInBeginSection": 1387, "offsetInEndSection": 1501, "text": "There was a significant correlation between EGFR gene copy number, EGFR gene mutations, and gefitinib sensitivity.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17145836", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 170, "text": "Epidermal growth factor receptor (EGFR) gene mutations have been found in a subset of non-small cell lung cancer (NSCLC) with good clinical response to gefitinib therapy.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16199108", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 262, "text": "Mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancers are associated with increased sensitivity of these cancers to drugs that inhibit EGFR kinase activity such as gefitinib and erlotinib.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16009451", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 204, "text": "Somatic mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene are reportedly associated with sensitivity of lung cancers to gefitinib (Iressa), kinase inhibitor.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15329413", "endSection": "sections.0"}, {"offsetInBeginSection": 1567, "offsetInEndSection": 1689, "text": "frequently containing mutations within the TK domain of EGFR that are associated with gefitinib and erlotinib sensitivity.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15329413", "endSection": "sections.0"}]}
{"body": "Which diseases that can be treated using the focused ultrasound thalamotomy.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26382842", "http://www.ncbi.nlm.nih.gov/pubmed/25438838", "http://www.ncbi.nlm.nih.gov/pubmed/27822200", "http://www.ncbi.nlm.nih.gov/pubmed/24291848", "http://www.ncbi.nlm.nih.gov/pubmed/25343176", "http://www.ncbi.nlm.nih.gov/pubmed/25512869", "http://www.ncbi.nlm.nih.gov/pubmed/24876191", "http://www.ncbi.nlm.nih.gov/pubmed/27399411", "http://www.ncbi.nlm.nih.gov/pubmed/26499271", "http://www.ncbi.nlm.nih.gov/pubmed/26421209", "http://www.ncbi.nlm.nih.gov/pubmed/24620914", "http://www.ncbi.nlm.nih.gov/pubmed/23944301", "http://www.ncbi.nlm.nih.gov/pubmed/20033983", "http://www.ncbi.nlm.nih.gov/pubmed/22208894", "http://www.ncbi.nlm.nih.gov/pubmed/23523144", "http://www.ncbi.nlm.nih.gov/pubmed/26769606", "http://www.ncbi.nlm.nih.gov/pubmed/24761224", "http://www.ncbi.nlm.nih.gov/pubmed/27557301", "http://www.ncbi.nlm.nih.gov/pubmed/26877873"], "ideal_answer": ["Focused ultrasound thalamotomy is used for treatment of Parkinson disease, essential tremor, obsessive-compulsive disorder and chronic neuropathic pain."], "exact_answer": [["Parkinson disease"], ["essential tremor"], ["obsessive-compulsive disorder"], ["chronic neuropathic pain"]], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D057086"], "type": "list", "id": "58846be0e56acf5176000005", "snippets": [{"offsetInBeginSection": 718, "offsetInEndSection": 927, "text": "Besides DBS and standard thalamotomy, novel surgical approaches for ET are on the horizon. The development of MRI-guided focused ultrasound technique has been the new frontier of deep brain lesional therapies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26382842", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 186, "text": "132 A Randomized, Sham-Controlled Trial of Transcranial Magnetic Resonance-Guided Focused Ultrasound Thalamotomy Trial for the Treatment of Tremor-Dominant, Idiopathic Parkinson Disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27399411", "endSection": "title"}, {"offsetInBeginSection": 158, "offsetInEndSection": 442, "text": "Recently, transcranial magnetic resonance-guided focused ultrasound (MRgFUS) has been used to successfully perform thalamotomy for essential tremor. We designed a double-blinded, randomized controlled trial to investigate the effectiveness of MRgFUS thalamotomy in tremor-dominant PD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27399411", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 398, "text": "Thalamotomy at the ventralis intermedius nucleus has been an effective treatment method for essential tremor, but how the brain network changes immediately responding to this deliberate lesion and then reorganizes afterwards are not clear. Taking advantage of a non-cranium-opening MRI-guided focused ultrasound ablation technique, we investigated functional network changes due to a focal lesion. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27822200", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "Unilateral magnetic resonance guided focused ultrasound thalamotomy for essential tremor: practices and clinicoradiological outcomes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24876191", "endSection": "title"}, {"offsetInBeginSection": 1482, "offsetInEndSection": 1637, "text": "CONCLUSIONS: Our results demonstrate that MRgFUS thalamotomy is a safe, effective and less-invasive surgical method for treating medication-refractory ET. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24876191", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 472, "text": "OBJECT: The authors report different MRI patterns in patients with essential tremor (ET) or obsessive-compulsive disorder (OCD) after transcranial MR-guided focused ultrasound (MRgFUS) and discuss possible causes of occasional MRgFUS failure.METHODS: Between March 2012 and August 2013, MRgFUS was used to perform unilateral thalamotomy in 11 ET patients and bilateral anterior limb capsulotomy in 6 OCD patients; in all patients symptoms were refractory to drug therapy. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25343176", "endSection": "abstract"}, {"offsetInBeginSection": 203, "offsetInEndSection": 421, "text": "To discern the neurophysiologic correlates of its therapeutic effects, we applied MRgHIFU to an intractable neurologic disorder, essential tremor, while measuring magnetoencephalogram mu rhythms from the motor cortex. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25438838", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "MRI Guided Focused Ultrasound Thalamotomy for Moderate-to-Severe Tremor in Parkinson's Disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26421209", "endSection": "title"}, {"offsetInBeginSection": 88, "offsetInEndSection": 416, "text": "Methods. Seven PD patients, mean age 59.4 ± 9.8 years (range, 46-74) with a mean disease duration of 5.4 ± 2.8 years (range, 2-10) suffering from severe refractory tremor, underwent ventral intermediate nucleus thalamotomy using MRI guided focused ultrasound (MRgFUS), an innovative technology that enables noninvasive surgery. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26421209", "endSection": "abstract"}, {"offsetInBeginSection": 1016, "offsetInEndSection": 1078, "text": "Thalamotomy using MRgFUS is safe and effective in PD patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26421209", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Evolution of Movement Disorders Surgery Leading to Contemporary Focused Ultrasound Therapy for Tremor.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26499271", "endSection": "title"}, {"offsetInBeginSection": 338, "offsetInEndSection": 463, "text": "A noninvasive approach using transcranial high-energy focused ultrasound has emerged for the treatment of intractable tremor.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26499271", "endSection": "abstract"}, {"offsetInBeginSection": 649, "offsetInEndSection": 775, "text": "This article describes the evolution of magnetic resonance-guided focused ultrasound for ventrolateral thalamotomy for tremor.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26499271", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 167, "text": "Thalamic connectivity in patients with essential tremor treated with MR imaging-guided focused ultrasound: in vivo fiber tracking by using diffusion-tensor MR imaging.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24620914", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 763, "text": "PURPOSE: To use diffusion-tensor (DT) magnetic resonance (MR) imaging in patients with essential tremor who were treated with transcranial MR imaging-guided focused ultrasound lesion inducement to identify the structural connectivity of the ventralis intermedius nucleus of the thalamus and determine how DT imaging changes correlated with tremor changes after lesion inducement.MATERIALS AND METHODS: With institutional review board approval, and with prospective informed consent, 15 patients with medication-refractory essential tremor were enrolled in a HIPAA-compliant pilot study and were treated with transcranial MR imaging-guided focused ultrasound surgery targeting the ventralis intermedius nucleus of the thalamus contralateral to their dominant hand.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24620914", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 69, "text": "A pilot study of focused ultrasound thalamotomy for essential tremor.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23944301", "endSection": "title"}, {"offsetInBeginSection": 168, "offsetInEndSection": 585, "text": "This preliminary study investigates the use of transcranial MRI-guided focused ultrasound thalamotomy for the treatment of essential tremor.METHODS: From February 2011 through December 2011, in an open-label, uncontrolled study, we used transcranial MRI-guided focused ultrasound to target the unilateral ventral intermediate nucleus of the thalamus in 15 patients with severe, medication-refractory essential tremor.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23944301", "endSection": "abstract"}, {"offsetInBeginSection": 1599, "offsetInEndSection": 1729, "text": "CONCLUSIONS: In this pilot study, essential tremor improved in 15 patients treated with MRI-guided focused ultrasound thalamotomy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23944301", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "MR-guided focused ultrasound thalamotomy for essential tremor: a proof-of-concept study.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23523144", "endSection": "title"}, {"offsetInBeginSection": 383, "offsetInEndSection": 566, "text": "MR-guided focused ultrasound has been developed as a non-invasive means of generating precisely placed focal lesions. We examined its application to the management of essential tremor", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23523144", "endSection": "abstract"}, {"offsetInBeginSection": 653, "offsetInEndSection": 818, "text": "Four patients with chronic and medication-resistant essential tremor were treated with MR-guided focused ultrasound to ablate tremor-mediating areas of the thalamus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23523144", "endSection": "abstract"}, {"offsetInBeginSection": 1540, "offsetInEndSection": 1739, "text": "INTERPRETATION: MR-guided focused ultrasound might be a safe and effective approach to generation of focal intracranial lesions for the management of disabling, medication-resistant essential tremor.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23523144", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Transcranial magnetic resonance imaging-guided focused ultrasound: noninvasive central lateral thalamotomy for chronic neuropathic pain.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22208894", "endSection": "title"}, {"offsetInBeginSection": 147, "offsetInEndSection": 493, "text": "The goal of this study was to apply the new transcranial magnetic resonance imaging-guided focused ultrasound (tcMRgFUS) technology to perform noninvasive central lateral thalamotomies (CLTs) as a treatment for chronic neuropathic pain.METHODS: In 12 patients suffering from chronic therapy-resistant neuropathic pain, tcMRgFUS CLT was proposed. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22208894", "endSection": "abstract"}, {"offsetInBeginSection": 2063, "offsetInEndSection": 2225, "text": "CONCLUSIONS: The authors assert that tcMRgFUS represents a noninvasive, precise, and radiation-free neurosurgical technique for the treatment of neuropathic pain.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22208894", "endSection": "abstract"}, {"offsetInBeginSection": 481, "offsetInEndSection": 585, "text": "A new less invasive treatment of tremor using MR guided focused ultrasound has started and is promising.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24291848", "endSection": "abstract"}, {"offsetInBeginSection": 1541, "offsetInEndSection": 1729, "text": "Quality-of-life scores improved from 37% to 11% (P=0.001).CONCLUSIONS: In this pilot study, essential tremor improved in 15 patients treated with MRI-guided focused ultrasound thalamotomy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23944301", "endSection": "abstract"}, {"offsetInBeginSection": 96, "offsetInEndSection": 413, "text": "Seven PD patients, mean age 59.4 ± 9.8 years (range, 46-74) with a mean disease duration of 5.4 ± 2.8 years (range, 2-10) suffering from severe refractory tremor, underwent ventral intermediate nucleus thalamotomy using MRI guided focused ultrasound (MRgFUS), an innovative technology that enables noninvasive surgery", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26421209", "endSection": "abstract"}, {"offsetInBeginSection": 490, "offsetInEndSection": 975, "text": "We hypothesized that all three would effectively treat the dominant hand and positively impact functional outcomes and quality of life as measured with the Clinical Rating Scale for Tremor and the Quality of Life in Essential Tremor Questionnaire.This is a retrospective study of medication-refractory essential tremor patients treated at the University of Virginia with bilateral Vim DBS (n = 57), unilateral Vim DBS (n = 13), or unilateral focused ultrasound Vim thalamotomy (n = 15)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26769606", "endSection": "abstract"}, {"offsetInBeginSection": 1510, "offsetInEndSection": 1684, "text": "Quality-of-life scores improved from 37% to 11% (P=0.001).In this pilot study, essential tremor improved in 15 patients treated with MRI-guided focused ultrasound thalamotomy", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23944301", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "MRI Guided Focused Ultrasound Thalamotomy for Moderate-to-Severe Tremor in Parkinsons Disease", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26421209", "endSection": "title"}, {"offsetInBeginSection": 97, "offsetInEndSection": 415, "text": "Seven PD patients, mean age 59.4 ± 9.8 years (range, 46-74) with a mean disease duration of 5.4 ± 2.8 years (range, 2-10) suffering from severe refractory tremor, underwent ventral intermediate nucleus thalamotomy using MRI guided focused ultrasound (MRgFUS), an innovative technology that enables noninvasive surgery.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26421209", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 553, "text": "Transcranial magnetic resonance imaging-guided high-intensity focused ultrasound (MRgHIFU) is gaining attention as a potent substitute for surgical intervention in the treatment of neurologic disorders. To discern the neurophysiologic correlates of its therapeutic effects, we applied MRgHIFU to an intractable neurologic disorder, essential tremor, while measuring magnetoencephalogram mu rhythms from the motor cortex. Focused ultrasound sonication destroyed tissues by focusing a high-energy beam on the ventralis intermedius nucleus of the thalamus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25438838", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 585, "text": "BACKGROUND: Recent advances have enabled delivery of high-intensity focused ultrasound through the intact human cranium with magnetic resonance imaging (MRI) guidance. This preliminary study investigates the use of transcranial MRI-guided focused ultrasound thalamotomy for the treatment of essential tremor.METHODS: From February 2011 through December 2011, in an open-label, uncontrolled study, we used transcranial MRI-guided focused ultrasound to target the unilateral ventral intermediate nucleus of the thalamus in 15 patients with severe, medication-refractory essential tremor.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23944301", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "MRI Guided Focused Ultrasound Thalamotomy for Moderate-to-Severe Tremor in Parkinson's Disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26421209", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 187, "text": "132 A Randomized, Sham-Controlled Trial of Transcranial Magnetic Resonance-Guided Focused Ultrasound Thalamotomy Trial for the Treatment of Tremor-Dominant, Idiopathic Parkinson Disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27399411", "endSection": "title"}, {"offsetInBeginSection": 1572, "offsetInEndSection": 1689, "text": "In this pilot study, essential tremor improved in 15 patients treated with MRI-guided focused ultrasound thalamotomy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23944301", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 75, "text": "A Randomized Trial of Focused Ultrasound Thalamotomy for Essential Tremor.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27557301", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "MR-guided focused ultrasound thalamotomy for essential tremor: a proof-of-concept study.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23523144", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Unilateral magnetic resonance guided focused ultrasound thalamotomy for essential tremor: practices and clinicoradiological outcomes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24876191", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Functional assessment and quality of life in essential tremor with bilateral or unilateral DBS and focused ultrasound thalamotomy.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26769606", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "Transcranial magnetic resonance imaging-guided focused ultrasound: noninvasive central lateral thalamotomy for chronic neuropathic pain.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22208894", "endSection": "title"}, {"offsetInBeginSection": 738, "offsetInEndSection": 977, "text": "This is a retrospective study of medication-refractory essential tremor patients treated at the University of Virginia with bilateral Vim DBS (n = 57), unilateral Vim DBS (n = 13), or unilateral focused ultrasound Vim thalamotomy (n = 15).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26769606", "endSection": "abstract"}, {"offsetInBeginSection": 635, "offsetInEndSection": 776, "text": "Twenty-one consecutive patients suffering from chronic (mean disease duration 29.9 years), therapy-resistant ET were treated with MRgFUS CTT.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26877873", "endSection": "abstract"}]}
{"body": "What is the effect of resveratrol on mTOR activity?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23272906", "http://www.ncbi.nlm.nih.gov/pubmed/23211629", "http://www.ncbi.nlm.nih.gov/pubmed/21966552", "http://www.ncbi.nlm.nih.gov/pubmed/23248098", "http://www.ncbi.nlm.nih.gov/pubmed/24060150", "http://www.ncbi.nlm.nih.gov/pubmed/22530672", "http://www.ncbi.nlm.nih.gov/pubmed/21168265", "http://www.ncbi.nlm.nih.gov/pubmed/21179458", "http://www.ncbi.nlm.nih.gov/pubmed/22269797", "http://www.ncbi.nlm.nih.gov/pubmed/22029423", "http://www.ncbi.nlm.nih.gov/pubmed/23680031", "http://www.ncbi.nlm.nih.gov/pubmed/19108833", "http://www.ncbi.nlm.nih.gov/pubmed/19827268", "http://www.ncbi.nlm.nih.gov/pubmed/19471118", "http://www.ncbi.nlm.nih.gov/pubmed/20851890", "http://www.ncbi.nlm.nih.gov/pubmed/22242130", "http://www.ncbi.nlm.nih.gov/pubmed/25448084", "http://www.ncbi.nlm.nih.gov/pubmed/20169165"], "ideal_answer": ["Resveratrol (RSV) inhibits leucine-stimulated mTORC1 activation by promoting mTOR/DEPTOR.", "Resveratrol downregulates PI3K/Akt/mTOR signaling pathways in human cells. It has been found that resveratrol targets multiple components of the phosphatidylinositol 3- kinase(PI3K)/Akt and mTOR signaling pathways, including PI3K, Akt, PTEN, and DEPTOR, suggesting that this natural compound and its derivatives may offer a promising new cancer treatment."], "concepts": ["http://www.uniprot.org/uniprot/MTOR_MOUSE", "http://www.uniprot.org/uniprot/MTOR_HUMAN", "http://www.biosemantics.org/jochem#4272358"], "type": "summary", "id": "551177626a8cde6b72000005", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "Resveratrol inhibits mTOR signaling by promoting the interaction between mTOR and DEPTOR", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20851890", "endSection": "title"}, {"offsetInBeginSection": 226, "offsetInEndSection": 359, "text": "Here, we show that RSV inhibits insulin- and leucine-stimulated mTOR signaling in C2C12 fibroblasts via a Sirt1-independent mechanism", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20851890", "endSection": "abstract"}, {"offsetInBeginSection": 361, "offsetInEndSection": 601, "text": "Treating C2C12 cells with RSV dramatically inhibited insulin-stimulated Akt, S6 kinase, and 4E-BP1 phosphorylation but had little effect on tyrosine phosphorylation of the insulin receptor and activation of the p44/42 MAPK signaling pathway", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20851890", "endSection": "abstract"}, {"offsetInBeginSection": 603, "offsetInEndSection": 790, "text": "RSV treatment also partially blocked mTOR and S6 kinase phosphorylation in TSC1/2-deficient mouse embryonic fibroblasts, suggesting the presence of an inhibitory site downstream of TSC1/2", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20851890", "endSection": "abstract"}, {"offsetInBeginSection": 1187, "offsetInEndSection": 1396, "text": "Taken together, our studies reveal that RSV inhibits leucine-stimulated mTORC1 activation by promoting mTOR/DEPTOR interaction and thus uncover a novel mechanism by which RSV negatively regulates mTOR activity", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20851890", "endSection": "abstract"}, {"offsetInBeginSection": 681, "offsetInEndSection": 824, "text": "Recent studies suggest that modulation of the mTOR signalling pathway could play an important role in mediating the beneficial effects of RSV. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24060150", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "Resveratrol inhibits the mTOR mitogenic signaling evoked by oxidized LDL in smooth muscle cells", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19108833", "endSection": "title"}, {"offsetInBeginSection": 1125, "offsetInEndSection": 1299, "text": "esveratrol blocked the oxLDL-induced phosphorylation and activation of the PI3K/Akt/mTOR/p70S6K pathway and strongly inhibited both the DNA synthesis and proliferation of SMC", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19108833", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "At concentrations that inhibit mTOR, resveratrol suppresses cellular senescence", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19471118", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 164, "text": "Here we demonstrated that, at cytostatic, near-toxic concentrations, resveratrol inhibited S6 phosphorylation and prevented the senescence morphology in human cells", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19471118", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "Resveratrol downregulates PI3K/Akt/mTOR signaling pathways in human U251 glioma cells", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19827268", "endSection": "title"}, {"offsetInBeginSection": 910, "offsetInEndSection": 1011, "text": "On the other hand, RSV significantly increased the association between mTOR and its inhibitor, DEPTOR", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20851890", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 55, "text": "Resveratrol inhibits mTOR signaling by targeting DEPTOR", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21966552", "endSection": "title"}, {"offsetInBeginSection": 206, "offsetInEndSection": 502, "text": "Recent studies suggest that suppressing the signaling pathway mediated by mTOR, a well-known energy sensor that integrates various hormonal, nutrient and environmental signals to regulate cell growth, metabolism and survival, could play an important role in mediating the beneficial effect of RSV", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21966552", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "Resveratrol engages AMPK to attenuate ERK and mTOR signaling in sensory neurons and inhibits incision-induced acute and chronic pain", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22269797", "endSection": "title"}, {"offsetInBeginSection": 778, "offsetInEndSection": 1018, "text": "Our results demonstrate that resveratrol profoundly inhibits ERK and mTOR signaling in sensory neurons in a time- and concentration-dependent fashion and that these effects are mediated by AMPK activation and independent of sirtuin activity", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22269797", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Resveratrol enhances the antitumor effects of temozolomide in glioblastoma via ROS-dependent AMPK-TSC-mTOR signaling pathway", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22530672", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 168, "text": "Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signaling.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21168265", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "Resveratrol inhibits mTOR signaling by promoting the interaction between mTOR and DEPTOR.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20851890", "endSection": "title"}, {"offsetInBeginSection": 1459, "offsetInEndSection": 1681, "text": "Consistent with the in vitro findings, resveratrol intervention in the PTEN knockout mouse model was associated with reduction in the prostatic levels of mTOR complex 1 (mTORC1) activity and increased expression of SIRT1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23248098", "endSection": "abstract"}, {"offsetInBeginSection": 482, "offsetInEndSection": 546, "text": "Resveratrol inhibited the phosphorylation of PI3K, AKT and mTOR.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21179458", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "Resveratrol inhibits the mTOR mitogenic signaling evoked by oxidized LDL in smooth muscle cells.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19108833", "endSection": "title"}, {"offsetInBeginSection": 1174, "offsetInEndSection": 1310, "text": "Resveratrol also alleviated the PI3K/Akt/mTOR signaling by down-regulation of Akt phosphorylation and up-regulation of PTEN expression.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25448084", "endSection": "abstract"}, {"offsetInBeginSection": 1095, "offsetInEndSection": 1272, "text": "Resveratrol blocked the oxLDL-induced phosphorylation and activation of the PI3K/Akt/mTOR/p70S6K pathway and strongly inhibited both the DNA synthesis and proliferation of SMC.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19108833", "endSection": "abstract"}, {"offsetInBeginSection": 683, "offsetInEndSection": 825, "text": "Resveratrol reduced phosphorylation of ribosomal protein S6 and the mTOR inhibitor rapamycin further enhanced resveratrol-induced cell death.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19827268", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "Resveratrol downregulates PI3K/Akt/mTOR signaling pathways in human U251 glioma cells.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19827268", "endSection": "title"}, {"offsetInBeginSection": 778, "offsetInEndSection": 1019, "text": "Our results demonstrate that resveratrol profoundly inhibits ERK and mTOR signaling in sensory neurons in a time- and concentration-dependent fashion and that these effects are mediated by AMPK activation and independent of sirtuin activity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22269797", "endSection": "abstract"}, {"offsetInBeginSection": 566, "offsetInEndSection": 695, "text": "The SIRT1 activator resveratrol reduces, whereas SIRT1 inhibitor nicotinamide enhances mTOR activity in a SIRT1 dependent manner.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20169165", "endSection": "abstract"}, {"offsetInBeginSection": 1087, "offsetInEndSection": 1257, "text": "We conclude that resveratrol is an inhibitor of global protein synthesis, and that this effect is mediated through modulation of mTOR-dependent and independent signaling.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22242130", "endSection": "abstract"}, {"offsetInBeginSection": 732, "offsetInEndSection": 888, "text": "RSV treatment has no effect on the expression levels of mTOR, raptor and DEPTOR, but greatly promotes the interaction between mTOR and its inhibitor DEPTOR.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21966552", "endSection": "abstract"}, {"offsetInBeginSection": 1187, "offsetInEndSection": 1397, "text": "Taken together, our studies reveal that RSV inhibits leucine-stimulated mTORC1 activation by promoting mTOR/DEPTOR interaction and thus uncover a novel mechanism by which RSV negatively regulates mTOR activity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20851890", "endSection": "abstract"}, {"offsetInBeginSection": 1012, "offsetInEndSection": 1184, "text": "Furthermore, the inhibitory effect of RSV on leucine-stimulated mTOR signaling was greatly reduced in cells in which the expression levels of DEPTOR were suppressed by RNAi", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20851890", "endSection": "abstract"}, {"offsetInBeginSection": 1468, "offsetInEndSection": 1688, "text": "Consistent with the in vitro findings, resveratrol intervention in the PTEN knockout mouse model was associated with reduction in the prostatic levels of mTOR complex 1 (mTORC1) activity and increased expression of SIRT1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23248098", "endSection": "abstract"}, {"offsetInBeginSection": 566, "offsetInEndSection": 694, "text": "The SIRT1 activator resveratrol reduces, whereas SIRT1 inhibitor nicotinamide enhances mTOR activity in a SIRT1 dependent manner", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20169165", "endSection": "abstract"}, {"offsetInBeginSection": 1140, "offsetInEndSection": 1298, "text": "However, most frequently, RSV is found to inhibit the activity of the mTOR pathway proteins, and to activate AMPK and LKB1, which can suppress mTOR signalling", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24060150", "endSection": "abstract"}, {"offsetInBeginSection": 276, "offsetInEndSection": 557, "text": "Over the past few years, numerous studies have suggested that suppressing the activity of mammalian target of rapamycin (mTOR), a critical regulator of cell metabolism, growth, and proliferation, may provide a key mechanism underlying the anticarcinogenic properties of resveratrol", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23272906", "endSection": "abstract"}, {"offsetInBeginSection": 1530, "offsetInEndSection": 1628, "text": "Resveratrol blocks specifically this pathway, thereby inhibiting oxLDL-induced SMC proliferation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19108833", "endSection": "abstract"}, {"offsetInBeginSection": 198, "offsetInEndSection": 300, "text": "Resveratrol causes cell cycle arrest and induces apoptotic cell death in various types of cancer cells", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19827268", "endSection": "abstract"}, {"offsetInBeginSection": 507, "offsetInEndSection": 575, "text": "Resveratrol decreased both the expression and phosphorylation of Akt", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19827268", "endSection": "abstract"}, {"offsetInBeginSection": 73, "offsetInEndSection": 119, "text": " Modulation of the AMPK, Akt and mTOR pathways", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22029423", "endSection": "title"}, {"offsetInBeginSection": 991, "offsetInEndSection": 1097, "text": "RSV (2.5-5 μM) inhibited clonogenic survival of PC3 and 22RV1 cells but not of normal prostate PNT1A cells", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22029423", "endSection": "abstract"}, {"offsetInBeginSection": 1413, "offsetInEndSection": 1513, "text": "RSV enhanced IR-activation of ATM and AMPK but inhibited basal and IR-induced phosphorylation of Akt", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22029423", "endSection": "abstract"}, {"offsetInBeginSection": 1528, "offsetInEndSection": 1755, "text": "Our results suggest that RSV arrests cell cycle, promotes apoptosis and sensitizes PrCa cells to IR likely through a desirable dual action to activate the ATM-AMPK-p53-p21(cip1)/p27(kip1) and inhibit the Akt signalling pathways", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22029423", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 111, "text": "Resveratrol pre-treatment reduces early inflammatory responses induced by status epilepticus via mTOR signaling", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23211629", "endSection": "title"}, {"offsetInBeginSection": 276, "offsetInEndSection": 558, "text": "Over the past few years, numerous studies have suggested that suppressing the activity of mammalian target of rapamycin (mTOR), a critical regulator of cell metabolism, growth, and proliferation, may provide a key mechanism underlying the anticarcinogenic properties of resveratrol.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23272906", "endSection": "abstract"}, {"offsetInBeginSection": 559, "offsetInEndSection": 840, "text": "It has been found that resveratrol targets multiple components of the phosphatidylinositol 3- kinase(PI3K)/Akt and mTOR signaling pathways, including PI3K, Akt, PTEN, and DEPTOR, suggesting that this natural compound and its derivatives may offer a promising new cancer treatment. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23272906", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "Autophagic cell death induced by resveratrol depends on the Ca(2+)/AMPK/mTOR pathway in A549 cells", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23680031", "endSection": "title"}, {"offsetInBeginSection": 1424, "offsetInEndSection": 1587, "text": "In conclusion, we demonstrate that resveratrol-induced A549 cell death was mediated by the process of autophagic cell death via Ca(2+)/AMPK-mTOR signaling pathway.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23680031", "endSection": "abstract"}]}
